Ocera secures CE mark and seeks partners for IBS therapy Zysa
This article was originally published in Scrip
Executive Summary
Ocera Therapeutics' spherical carbon adsorbent Zysa for the treatment of diarrhoea-predominant irritable bowel syndrome (D-IBS) is on two different paths in the US and in the EU, where the oral product has just received its CE Mark, denoting conformity with EU standards.
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.